CanSino Biologics Inc. convened its 2025 Annual Scientific Advisory Board Meeting on October 16, 2025, in Tianjin. At the event, the company reviewed progress and future plans for several key vaccine projects, including tuberculosis, pneumococcal, pediatric DTcP, adolescent and adult Tdcp vaccines, as well as its mRNA technology platform.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief on October 16, 2025, and is solely responsible for the information contained therein.
Comments